Important Safety Information and Indication
DETROL® LA (tolterodine tartrate extended release capsules) is contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma.
Anaphylaxis and angioedema requiring hospitalization and emergency medical treatment have occurred with the first or subsequent doses of
DETROL LA capsules should be used with caution in patients with clinically significant bladder outflow obstruction, gastrointestinal obstructive disorders, controlled narrow-angle glaucoma, myasthenia gravis, and QTc prolongation.
DETROL LA is associated with anticholinergic central nervous system (CNS) effects including dizziness and somnolence. Advise patients not to drive or operate heavy machinery until
The recommended dose of DETROL LA capsules is
The most frequently reported adverse events (≥4%) for
DETROL LA is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.